ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : Lymphocytic Hypophysitis
Clear All
Filter by Field of Research
Haematology (4)
Haematological Tumours (2)
Gene Expression (incl. Microarray and other genome-wide approaches) (1)
Immunology (1)
Nutritional science (1)
Pharmacology and Pharmaceutical Sciences not elsewhere classified (1)
Protein Targeting And Signal Transduction (1)
Tumour Immunology (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (13)
Filter by Status
Closed (13)
Filter by Scheme
NHMRC Project Grants (5)
NHMRC Postgraduate Scholarships (3)
Project Grants (3)
Postgraduate Scholarships (1)
Research Fellowships (1)
Filter by Country
Australia (2)
Filter by Australian State/Territory
NSW (1)
WA (1)
  • Researchers (0)
  • Funded Activities (13)
  • Organisations (0)
  • Funded Activity

    Characterisation Of Pituitary Target Autoantigens

    Funder
    National Health and Medical Research Council
    Funding Amount
    $173,380.00
    Summary
    This study is investigating an autoimmune disease called lymphocytic hypophysitis, involving the master gland in the body, the pituitary. It often affects pregnant women and is under diagnosed. The aim of our study is to determine the cause of this disease and its unexplained link with pregnancy. We are also working on a new diagnostic test which will enable doctors to confirm the diagnosis by serological means. At present, invasive pituitary biopsy is needed. Whilst developing this new test, we .... This study is investigating an autoimmune disease called lymphocytic hypophysitis, involving the master gland in the body, the pituitary. It often affects pregnant women and is under diagnosed. The aim of our study is to determine the cause of this disease and its unexplained link with pregnancy. We are also working on a new diagnostic test which will enable doctors to confirm the diagnosis by serological means. At present, invasive pituitary biopsy is needed. Whilst developing this new test, we have identified three proteins and their genes. This information may have major implications for the study of pituitary gland function.
    Read more Read less
    More information
    Funded Activity

    Identifiaction Of The Target Autoantigens In Lymphocytic Hypophysitis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $42,069.00
    More information
    Funded Activity

    Studies Into The Pathogenesis Of Lymphocytic Colitis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $41,892.00
    More information
    Funded Activity

    TACI: A Novel Immune Checkpoint In Chronic Lymphocytic Leukemia

    Funder
    National Health and Medical Research Council
    Funding Amount
    $874,462.00
    Summary
    Chronic Lymphocytic Leukemia (CLL) is a very common blood cancer. CLL cells actively shut down immune defenses in patients. Moreover, current as well as emerging more targeted therapies suppress immunity and over a quarter of patients will die from an infection despite a good response to cancer treatments. Our laboratory has gained new understanding in the mechanism of action of a new treatment for CLL called Ibrutinib. This information allows us to design improved treatment options for CLL.
    More information
    Funded Activity

    MRNA Expression Profiling Of Chronic Lymphocytic Leukaemia (CLL) Cells From In Vivo Hypoxic Microenvironmental Niches; Applications For In Vitro Research And Clinical Management.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $124,676.00
    Summary
    Chronic lymphocytic lymphoma (CLL) is the most frequently diagnosed leukaemia in adults and is still considered incurable. CLL cells proliferate in the lymph nodes and bone marrow; these are areas of the human body that are hypoxic when compared to blood. These hypoxic areas affect CLL cell survival, proliferation and treatment resistance. Changes that occur to CLL cells in these areas can be measured by gene expression profiling and modeled in a lab setting to identify targets for treatment.
    More information
    Funded Activity

    Role Of The P2X7 Receptor In The Pathogenesis Of Chronic B-cell Malignancies.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $19,659.00
    More information
    Funded Activity

    Regulation And Mechanisms Of Cytotoxic Lymphocyte Function

    Funder
    National Health and Medical Research Council
    Funding Amount
    $631,010.00
    Summary
    The immune system is the essential complex barrier that protects the organism for infections and some malignancies. Despite considerable efforts, the mechanism by which immune cells kill dangerous unwanted cells is poorly understood. This project will investigate the mechanism of action and the role in human pathologies of a key component of the immune system, a toxic protein perforin.
    More information
    Funded Activity

    CHARACTERISATION AND ANTIBODY-MEDIATED TARGETING OF A NOVEL SPECIFIC MARKER FOR T CELL ALL/LYMPHOBLASTIC LYMPHOMA

    Funder
    National Health and Medical Research Council
    Funding Amount
    $586,146.00
    Summary
    Improvements in treatment have seen some types of leukaemia (a cancer of white blood cells) being curable in up to 90% of patients with the disease; however, other types of leukaemia do not respond to these drugs and new approaches are needed. We have discovered that some leukaemia cells express a unique protein not made by any other cell type. This project will analyse how this aberrant protein is made and how this process contributes to the development of leukaemia. Also, since this protein is .... Improvements in treatment have seen some types of leukaemia (a cancer of white blood cells) being curable in up to 90% of patients with the disease; however, other types of leukaemia do not respond to these drugs and new approaches are needed. We have discovered that some leukaemia cells express a unique protein not made by any other cell type. This project will analyse how this aberrant protein is made and how this process contributes to the development of leukaemia. Also, since this protein is unique to the leukaemia cells, it offers the opportunity to develop magic bullets able to target specifically to the leukaemia cells and to kill them. This project aims to make one such drug and to conduct preliminary testing.
    Read more Read less
    More information
    Funded Activity

    Impact Of Aberrant Branchpoint Selection In Myelodysplasia And Chronic Lymphocytic Leukaemia.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $605,326.00
    Summary
    Most human genes are spliced together from smaller exon parts. CIA Mercer has found that if splicing proceeds incorrectly backwards, small circular RNAs and incomplete genes are built. The splicing machinery responsible for this process is recurrently mutated in blood disorders, notably Myelodysplasia and Chronic Lymphocytic Leukaemia. We propose that these mutations cause backwards splicing of key genes responsible for these disorders, representing a major new pathway to cancer.
    More information
    Funded Activity

    Redirecting T-cells For Immunotherapy Of Leukaemia And Lymphoma By The Expression Of A CD19-specific Chimeric Antigen Receptor Using The PiggyBac Transposon Gene Modification System

    Funder
    National Health and Medical Research Council
    Funding Amount
    $374,876.00
    Summary
    Most lymphomas respond to therapy but then relapse. Immune cells can attack and kill virus related lymphomas. However, most lymphomas are NOT virus related. We will create immune cells targeting these virus negative lymphomas by inserting artificial receptors into the immune cells. These receptors attach to the lymphoma and activate the immune cells. The immune cells will home to the lymphoma, kill lymphoma cells and persist in the body for many years, preventing lymphoma relapse.
    More information

    Showing 1-10 of 13 Funded Activites

    • 1
    • 2
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback